Nishank Jain
Associate Professor
Also affiliated: Rush University Medical Center (2024); University of Arizona (2021); University of Connecticut (2008); University of Arkansas Medical Center (2016–2025); Veterans Health Administration (2021); University of Alabama at Birmingham (2011); Central Arkansas Veterans Healthcare System (2017–2024); VA North Texas Health Care System (2012–2014); Rochester General Hospital (2026); University of Kansas Medical Center (2015–2016); Central Alabama Veterans Health Care System (2017); The University of Texas Southwestern Medical Center (2011–2014)
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Nishank Jain, MD, MPH, studies the role of platelets in chronic kidney disease (CKD) pathophysiology and the use of antiplatelet agents in patients with kidney diseases. He is an Associate Professor in the Department of Medicine at the University of Arkansas for Medical Sciences. Dr. Jain received his medical degree and completed his fellowship in nephrology and hypertension at UT Southwestern Medical Center. His research has been supported by grants from the American Heart Association, the National Institutes of Health/National Heart, Lung, and Blood Institute, and institutional career development awards.
His federally funded research, totaling $700,797 from the NIH/NHLBI, investigates the effect of platelet inhibition with ticagrelor on inflammation and surrogate cardiovascular markers in patients with CKD. Dr. Jain also leads a research group and has published extensively on various aspects of CKD, including hyperkalemia, depressive symptoms, fatigue, and the utility of cardiac biomarkers. He has a scholarship record with an h-index of 17, 1,282 citations, and 68 total publications.
Beyond his research, Dr. Jain is committed to medical education, focusing on training and engaging medical students in academic medicine. He has received teaching awards and facilitated student participation in research presentations at national meetings.
Research Overview
Nishank Jain, MD, MPH, is a nephrologist and an Associate Professor in the Department of Medicine at University of Arkansas for Medical Sciences, Little Rock, AR. He completed his clinical and research fellowship at UT Southwestern Medical Center, Dallas, TX, before joining as a faculty member. His research interest is in the role of platelets in CKD pathophysiology and use of antiplatelet agents in patients with kidney diseases. He has been funded by post-doctoral fellowship grant from the American Heart Association (AHA), institutional KL2 grant and career development grants from the American Society of Nephrology and the AHA. Dr. Jain is passionate about education and is driven by training and engaging medical students for a career in academic medicine. He has also helped medical students receive Honors in Research upon graduation. Dr. Jain has received medical student teaching awards. He has also engaged in SSCI activities by sending medical students to present original research work at the Annual Meetings.
Metrics
- h-index: 17
- Publications: 68
- Citations: 1,285
Positions
-
Associate Program Director, Internal Medicine Residency 2024–presentUniversity of Arkansas for Medical Sciences ORCID
-
Associate Professor with tenure 2022–presentUniversity of Arkansas for Medical Sciences Medicine ORCID
-
Associate Professor publications 2016–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
-
Assistant Professor 2016–2022University of Arkansas for Medical Sciences ORCID
Selected Publications
-
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality (2026)
-
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease (2026)
-
Hydrocortisone Use for Septic Shock in Patients With CKD (2026)
-
Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease. (2026)
-
26-A-10911-ACC EFFECT OF GLUCAGON-LIKE RECEPTOR PEPTIDE-1 AGONISTS ON ATRIAL FIBRILLATION-RELATED EVENTS AND INCIDENCE IN CHRONIC KIDNEY DISEASE (2026)
-
Fungal DNA in Circulation (2025)
-
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)
-
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients (2025)
-
Sepsis-Related Hospitalization and Mortality in Patients with CKD (2025)
-
Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation (2025)
-
Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD (2025)
-
Higher Glycolysis in Circulating Leukocytes in Patients with CKD (2024)
-
Platelets, inflammation, and purinergic receptors in chronic kidney disease (2024)
-
P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis (2024)
-
EFFICACY AND OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND ESRD (2024)
Federal Grants 1 $700,797 total
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Glycolysis in Leukocytes and Inflammation in Patients with CKD Dialysis Clinic, Inc. Principal Investigator
- Platelet, Inflammation and Thrombosis in Chronic Kidney Disease NIH/NCATS Principle Investigator
- Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
- Effectiveness and safety of clopidogrel, prasugrel and ticagrelor in patients with end stage renal disease (ESCALATE) American Heart Association Principal Investigator
- PREDICT-BLEED study Translational Research Institute, UAMS Principal Investigator
- A Mechanistic Study in Patients with Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study) American Society of Nephrology Foundation for Kidney Research Principal Investigator
- Study of uremic toxins and levels of antiplatelet therapy to investigate mechanisms of excessive stroke in patients with chronic kidney disease UAMS Office of Research Principal Investigator
Collaboration Network
Top Collaborators
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
Showing 5 of 10 shared publications
- Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence
- Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes
- Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes
- Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
Showing 5 of 9 shared publications
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
Showing 5 of 8 shared publications
- Role of Platelets in Chronic Kidney Disease
- Association of platelet function with depression and its treatment with sertraline in patients with chronic kidney disease: analysis of a randomized trial
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
Showing 5 of 6 shared publications
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Authors' Reply: Platelet Count, Platelet Volume and CKD
Showing 5 of 6 shared publications
- Updates on New Therapies for Patients with CKD
- Platelets, inflammation, and purinergic receptors in chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Authors' Reply: Platelet Count, Platelet Volume and CKD
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
Showing 5 of 6 shared publications
- Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
- Accurate Medication Adherence Measurement Using Administrative Data for Frequently Hospitalized Patients
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
- Updates on New Therapies for Patients with CKD
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- 438 Platelets, Inflammation and Thrombosis in Chronic Kidney Disease
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- Sepsis-Related Hospitalization and Mortality in Patients with CKD
- 26-A-10911-ACC EFFECT OF GLUCAGON-LIKE RECEPTOR PEPTIDE-1 AGONISTS ON ATRIAL FIBRILLATION-RELATED EVENTS AND INCIDENCE IN CHRONIC KIDNEY DISEASE
- Hydrocortisone Use for Septic Shock in Patients With CKD
- GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Renal Biomarkers in Heart Failure
- Platelet Count and Platelet Volume in Patients with CKD
- Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis
- Role of Platelets in Chronic Kidney Disease
- Platelets, inflammation, and purinergic receptors in chronic kidney disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
- Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence
- Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes
- Effect Modification of Chronic Kidney Disease on the Association of Circulating and Imaging Cardiac Biomarkers With Outcomes
Similar Researchers
Based on overlapping research topics